Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

Tóm tắt

Abstract In a phase 2 study, 62 patients with relapsed and refractory acute myeloid leukemia (AML; n = 31), myelodysplastic syndrome (MDS; n = 8), chronic myeloid leukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/m2 clofarabine intravenously over 1 hour daily for 5 days, every 3 to 6 weeks. Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 (15%) achieved CR but without platelet recovery (CRp), for an overall response rate of 48%. In AML, responses were noted in 2 (18%) of 11 patients in first salvage with short first CR (≤ 12 months), in 7 (87%) of 8 patients with longer first CR, and in 8 (67%) of 12 patients in second or subsequent salvage. Responses were observed in 4 of 8 patients with high-risk MDS (50%), in 7 (64%) of 11 with CML-BP, and in 2 (17%) of 12 with ALL. Severe reversible liver dysfunction was noted in 15% to 25%. After the first clofarabine infusion, responders accumulated more clofarabine triphosphate in blasts compared with nonresponders (median 18 vs 10 μM; P = .03). This increased only in responders (median, 1.8-fold; P = .008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance. (Blood. 2003;102:2379-2386)

Tài liệu tham khảo

Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331: 896-903. Fosså A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17: 3786-3792. Silverman LR, Demakos EP, Bercedis L, et al. A randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20: 2429-2440. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18: 956-962. Goodman GR, Burian C, Koziol JA, Saven, A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21: 891-896. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19: 2142-2132. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92: 1165-1171. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12: 671-678. Warrell R, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4: 74-79. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46: 5953-5958. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84: 3429-3434. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-b-D-arabinofuranosyladenine. J Med Chem. 1992;35: 397-401. Avramis VI, Plunkett W. 2-Fluoro-ATP: a toxic metabolite of 9-b-D-arabinofuranosyl-2-fluoroadenine. Biochem Biophys Res Comm. 1983;113: 35-43. Avramis VI, Plunkett W. Metabolism of 9-b-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate by mice bearing P388 leukemia. Cancer Drug Delivery. 1983;1: 1-10. Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-b-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli: a pathway for 2-fluoro-ATP production. Biochem Pharm. 1987;36: 2945-2952. Parker WB, Allan PW, Hassan AE, Secrist JA III, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10: 23-29. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′deoxyadenosine. Proc Natl Acad Sci U S A. 1992;89: 2970-2974. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-trisphosphate. Cancer Res. 1991;51: 2386-2394. Parker WB, Shaddix SC, Rose LM., et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-b-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2,2-difluoro-b-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol. 1999;55: 515-520. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs: cancer chemotherapy and biological response modifiers. In: Giaccone G, Schilsky R, Sondel P, eds. Annual 19. Amsterdam, The Netherlands: Elsevier Science BV; 2001: 21-45. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34: 485-491. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res. 1995;55: 2847-2852. Xie KC, Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-b-D-arabinofuranosyl)adenine. Cancer Res. 1996;56: 3030-3037. Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine (CI-F-ara-A; 2 chloro-2′-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) in patients with solid and hematologic cancers. J Clin Oncol. 2003;21: 1167-1173. Plunkett W, Hug V, Keating M, et al: Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-ß-D-arabinofuranosylcytosine therapy. Cancer Res. 1980;40: 588-591. Gandhi V, Chen W, Ayres M, et al. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002;50: 85-94. Rodriguez CO Jr, Plunkett W, Paff MT, et al. A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatography B. 2002;745: 421-430. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001;9: 2804-2811. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia Lymphoma. 1993;10: 49-56. Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998;4: 653-658. Kemena A, Gandhi V, Shewach D, Keating MJ, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992;31: 193-199. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11: 116-124. Crews KR, Gandhi V, Srivastava DK, et al. An interim analysis of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20: 4217-4224. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87: 156-164. Jeha S, Gandhi V, Chan KW, et al. Phase I study of clofarabine (Clofarex™) in pediatric leukemia [abstract]. Blood. 2002;100: 86a. Foran J, Wetzler M, Kantarjian H, et al. A phase II, open-label study of Clofarex™ in adult patients with refractory or relapsed acute myelogenous leukemia [abstract]. Blood. 2002;100: 271b. Jeha S, Steinherz P, Altman A, et al. A phase II, open-label study of Clofarex™ in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia [abstract]. Blood. 2002;100: 271b. Gandhi V, Huang P, Chapman AJ, et al. Incorporation of fludarabine- and arabinosylcytosine-5′-triphosphates by DNA polymerase a: affinity, interaction, and consequences. Clin Cancer Res. 1997;3: 1347-1355. Cooper T, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine [abstract]. Proc AACR. 2003;44: 142. Yamauchi T, Nowak B, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7: 3580-3589.
Thông tin
Thông tin xuất bản
Chưa có thông tin xuất bản
Thông tin tác giả